In addition to meeting the primary endpoint of superior A1C reduction, the once-daily oral pill reduced weight by an average ...

In Phase III MINT trial, Uplizna (inebilizumab) demonstrated significant short-term efficacy and a manageable safety profile ...

Alector has announced the completion of enrollment for its Phase II clinical trial, PROGRESS-AD, evaluating the safety and ...

Adding Farxiga (dapagliflozin) to standard care significantly reduced the risk of death or worsening heart failure in older ...

Results from a subgroup of the ICONIC-LEAD study show 75% of adolescents with plaque psoriasis achieved completely clear skin ...

Examining the implications of the recent US executive orders concerning diversity, equity, and inclusion pursuits—and the key ...

In this video interview, Derek Ansel, vice president, therapeutic strategy lead, rare disease, Worldwide Clinical Trials, ...

With close collaboration between sponsors, CROs, and regulators, this emerging technology has the potential to greatly ...

In the Phase III EXPECTS trial, patients experiencing mostly mild posterior circulation ischemic stroke who were ineligible ...

In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a ...

In this video interview, Derek Ansel, vice president, therapeutic strategy lead, rare disease, Worldwide Clinical Trials, discusses how artificial intelligence can aid in bringing therapies to rare ...

In this video interview, Thierry Escudier, portfolio lead, Pistoia Alliance, highlights where regulatory agencies currently ...